The United States Patent and Trademark Office (USPTO) has published patent application US20260083696A1, titled 'Gamma-hydroxybutyrate formulations with improved pharmacokinetics.' This application, filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson, describes novel modified release formulations of gamma-hydroxybutyrate designed to enhance dissolution and pharmacokinetic properties.

This publication represents a new patent filing and does not impose immediate compliance obligations. However, it is relevant for pharmaceutical companies and drug manufacturers involved in the development or research of gamma-hydroxybutyrate or similar formulations. Compliance officers should note this filing as it pertains to intellectual property within the pharmaceutical sector, potentially impacting future product development and market exclusivity.